Phase II study of pembrolizumab (pembro) and bavituximab (bavi) in advanced hepatocellular carcinoma (HCC)

被引：2
|
作者：
Hsiehchen, D. [1 ]
Kainthla, R. [1 ]
Zhu, H. [1 ]
Jones, A. [1 ]
Beg, M. S. [1 ]
机构：
[1] UTSW Univ Texas Southwestern Med Ctr, Hematol & Oncol, Dallas, TX USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.159
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
939P
引用
收藏
页码：S822 / S823
页数：2
相关论文
共 50 条
  • [1] Phase 2 trial of pembrolizumab (pembro) and bavituximab (bavi) in advanced hepatocellular carcinoma (HCC).
    Hsieh, David
    Kainthla, Radhika
    Zhu, Hao
    Beg, Muhammad S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 584 - 584
  • [2] A Phase II Study of Bavituximab and Sorafenib in Advanced Hepatocellular Carcinoma (HCC)
    Yopp, A.
    Zhu, H.
    Mansour, J.
    Singal, A.
    Arriaga, Y.
    Beg, S.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S34 - S35
  • [3] A phase II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC).
    Yopp, Adam Charles
    Singal, Amit G.
    Arriaga, Yull Edwin
    Verma, Udit N.
    Shan, Joseph
    Kallinteris, Nikoletta
    Beg, Muhammad Shaalan
    Mansour, John C.
    Zhu, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [4] A phase I/II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC)
    Yopp, Adam Charles
    Singal, Amit G.
    Arriaga, Yull Edwin
    Verma, Udit N.
    Shan, Joseph
    Kallinteris, Nikoletta L.
    Beg, Muhammad Shaalan
    Mansour, John C.
    Zhu, Hao
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Updated efficacy and safety of KEYNOTE-224: A phase II study of pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC)
    Kudo, Masatoshi
    Finn, Richard S.
    Edeline, Julien
    Cattan, Stephane
    Ogasawara, Sadahisa
    Palmer, Daniel H.
    Verslype, Chris
    Zagonel, Vittorina
    Fartoux, Laetitia
    Vogel, Arndt
    Sarker, Debashis
    Verset, Gontran
    Chan, Stephen Lam
    Knox, Jennifer J.
    Daniele, Bruno
    Gurary, Ellen B.
    Siegel, Abby B.
    Jain, Lokesh
    Cheng, Ann-Lii
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [6] Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study.
    Van Laethem, Jean-Luc
    Borbath, Ivan
    Karwal, Mark
    Verslype, Chris
    Van Vlierberghe, Hans
    Kardosh, Adel
    Zagonel, Vittorina
    Stal, Per
    Sarker, Debashis
    Palmer, Daniel H.
    Vogel, Arndt
    Edeline, Julien
    Cattan, Stephane
    Kudo, Masatoshi
    Cheng, Ann-Lii
    Ogasawara, Sadahisa
    Siegel, Abby B.
    Chisamore, Michael Jon
    Wang Anran
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [7] A phase I study of bavituximab and sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Yopp, Adam
    Arriega, Yuii
    Singal, Amit
    Mansour, John
    Bach, Glen
    Thorpe, Phillip
    CANCER RESEARCH, 2012, 72
  • [8] Phase II study of bavituximab (bavi), a first-in-class antibody targeting phosphatidylserine (PS), plus pembrolizumab (pembro) in advanced gastric or gastroesophageal junction (GEJ) cancer
    Chau, I.
    Culm-Merdek, K.
    Bendell, J. C.
    Catenacci, D. V.
    Lee, J.
    Chaney, M. F.
    MacIntyre, S.
    Gopal, S.
    Santos, V. Chamberlain
    Youssoufian, H.
    Mockbee, C.
    Benjamin, L.
    Park, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S1050 - S1051
  • [9] Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase 2 KEYNOTE-224 study.
    Van Laethem, Jean-Luc
    Borbath, Ivan
    Karwal, Mark
    Verslype, Chris
    Van Vlierberghe, Hans
    Kardosh, Adel
    Zagonel, Vittorina
    Stal, Per
    Sarker, Debashis
    Palmer, Daniel H.
    Vogel, Arndt
    Edeline, Julien
    Cattan, Stephane
    Kudo, Masatoshi
    Cheng, Ann-Lii
    Ogasawara, Sadahisa
    Siegel, Abby B.
    Chisamore, Michael Jon
    Wang, Anran
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC)
    El-Khoueiry, Anthony B.
    Kim, Richard D.
    Harris, William P.
    Sung, Max W.
    Waldschmidt, Dirk
    Iqbal, Syma
    Zhang, Xiaojing
    Nakajima, Keiko
    Galle, Peter R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345